EUVIMEDEUVIMED entdecken
Crossref

Optimizing Sample Size Determinations for Phase 3 Clinical Trials in Type 2 Diabetes

Alexander C Cambon iD, James Travis, Liping Sun, Jada Idokogi, Anna Kettermann

Pharmaceutical Statistics · 2025

DOI: 10.1002/pst.2446 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Pharmaceutical Statistics, 2025. Verfasst von Alexander C Cambon und 4 weiteren Autor:innen. Beteiligte Einrichtung: FDA Center for Drug Evaluation and Research, Office of Translational Science, Office of Biostatistics, Silver Spring, Maryland, USA. Hauptthemen laut MEDLINE: Diabetes Mellitus, Type 2, Clinical Trials, Phase III as Topic, Randomized Controlled Trials as Topic, Hypoglycemic Agents. Die Arbeit nennt 15 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

An informed estimate of subject‐level variance is a key determinate for accurate estimation of the required sample size for clinical trials. Evaluating completed adult Type 2 diabetes studies submitted to the FDA for accuracy of the variance estimate at the planning stage provides insights to inform the sample size requirements for future studies. From the U.S. Food and Drug Administration (FDA) database of new drug applications containing 14,106 subjects from 26 phase 3 randomized studies submitted to the FDA in support of drug approvals in adult type 2 diabetes studies reviewed between 2013 and 2017, we obtained estimates of subject‐level variance for the primary endpoint—change in glycated hemoglobin (HbA1c) from baseline to 6 months. In addition, we used nine additional studies to examine the impact of clinically meaningful covariates on residual standard deviation and sample size re‐estimation. Our analyses show that reduced sample sizes can be used without interfering with the validity of efficacy results for adult type 2 diabetes drug trials. This finding has implications for future research involving the adult type 2 diabetes population, including the potential to reduce recruitment period length and improve the timeliness of results. Furthermore, our findings could be utilized in the design of future endocrinology clinical trials.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Diabetes Mellitus, Type 2Clinical Trials, Phase III as TopicRandomized Controlled Trials as TopicHypoglycemic AgentsHumansSample SizeGlycated HemoglobinUnited StatesUnited States Food and Drug AdministrationResearch DesignDatabases, FactualAdult

Stichwörter der Autor:innen

diabetessample size estimationvariance

Substanzen

Hypoglycemic AgentsGlycated Hemoglobinhemoglobin A1c protein, human

Autor:innen und Institutionen

  • FDA Center for Drug Evaluation and Research, Office of Translational Science, Office of Biostatistics, Silver Spring, Maryland, USA.
  • Janssen R&D, Clinical Biostatistics, Statistics and Decision Sciences, Spring House, Pennsylvania, USA.

ORCID-Profile: Alexander C Cambon

Zitieren

APA

Cambon, A. C., Travis, J., Sun, L., Idokogi, J., & Kettermann, A. (2025). Optimizing Sample Size Determinations for Phase 3 Clinical Trials in Type 2 Diabetes. Pharmaceutical Statistics. https://doi.org/10.1002/pst.2446

Vancouver

Cambon AC, Travis J, Sun L, Idokogi J, Kettermann A. Optimizing Sample Size Determinations for Phase 3 Clinical Trials in Type 2 Diabetes. Pharmaceutical Statistics. 2025. doi:10.1002/pst.2446

BibTeX
@article{Cambon2025,
  author = {Cambon, Alexander C and Travis, James and Sun, Liping and Idokogi, Jada and Kettermann, Anna},
  title = {Optimizing Sample Size Determinations for Phase 3 Clinical Trials in Type 2 Diabetes},
  journal = {Pharmaceutical Statistics},
  year = {2025},
  doi = {10.1002/pst.2446}
}
Kostenlos starten →